マルチがん早期スクリーニングの世界市場：市場レポート、競合分析、地域別機会 (2025年～2031年)

当レポートは、マルチがん早期スクリーニング (Multi-Cancer Early Screening) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

• 調査範囲
• 市場：タイプ別
  • 世界のタイプ別市場成長: 2020 VS 2024 VS 2031
  • cfDNA Methylation
  • Low-pass WGS
  • Protein Marker Combination
  • Multi-omics Integrated Analysis
• 市場：用途別
  • 世界の用途別市場シェア: 2020 VS 2024 VS 2031
  • Medical Institutions
  • Physical Examination Centers
• 前提条件と制限
• 調査目的
• 対象期間

第2章 世界の市場成長トレンド

• 世界のマルチがん早期スクリーニングの市場展望 (2020-2031)
• 世界の市場規模：地域別: 2020 VS 2024 VS 2031
• 世界のマルチがん早期スクリーニングの収益市場シェア 地域別 (2020-2025)
• 世界のマルチがん早期スクリーニングの収益予測：地域別 (2026-2031)
• 主要地域と新興市場分析
  • 北米のマルチがん早期スクリーニング 市場規模および予測 (2020-2031)
  • 欧州のマルチがん早期スクリーニング 市場規模および予測 (2020-2031)
  • 中国のマルチがん早期スクリーニング 市場規模および予測 (2020-2031)
  • 日本のマルチがん早期スクリーニング 市場規模および予測 (2020-2031)
  • 東南アジア マルチがん早期スクリーニング 市場規模および予測 (2020-2031)
  • インド マルチがん早期スクリーニング 市場規模および予測 (2020-2031)
  • 南アメリカ マルチがん早期スクリーニング 市場規模および予測 (2020-2031)
  • 中東 マルチがん早期スクリーニング 市場規模および予測 (2020-2031)

第3章 内訳データ：タイプ別

• 世界のマルチがん早期スクリーニングの市場規模実績：タイプ別 (2020-2025)
• 世界のマルチがん早期スクリーニングの市場規模予測：タイプ別 (2026-2031)
• 各種タイプ マルチがん早期スクリーニング 代表的な企業

第4章 内訳データ：用途別

• 世界のマルチがん早期スクリーニングの市場規模実績：用途別 (2020-2025)
• 世界のマルチがん早期スクリーニングの市場規模予測：用途別 (2026-2031)
• 新たな成長源 マルチがん早期スクリーニング アプリケーション

第5章 競合他社の状況

• 世界トップ企業 収益
  • 世界のマルチがん早期スクリーニングの上位企業：収益別 (2020-2025)
  • 世界のマルチがん早期スクリーニングの収益シェア：企業別 (2020-2025)
• 世界の企業タイプ別市場シェア (Tier 1, Tier 2, and Tier 3)
• 企業ランキング： マルチがん早期スクリーニング 収益
• 世界のマルチがん早期スクリーニング 市場集中度分析
  • 世界のマルチがん早期スクリーニング 市場集中度 (CR5 and HHI)
  • 世界の上位10・上位5企業： マルチがん早期スクリーニング 収益 2024年
• 世界の主要企業 マルチがん早期スクリーニング 本社 および提供地域
• 世界の主要企業 マルチがん早期スクリーニング, 製品およびアプリケーション
• 世界の主要企業 マルチがん早期スクリーニング, 業界参入時期
• M&A, 拡張計画

第6章 地域分析

• 北米の市場: Pレイヤー, セグメントs and 下流
  • 北米のマルチがん早期スクリーニング 企業別収益 (2020-2025)
  • 北米の市場規模：タイプ別
  • 北米の市場規模：用途別
  • 北米の市場 トレンドと機会
• 欧州の市場: Pレイヤー, セグメントs and 下流
  • 欧州のマルチがん早期スクリーニング 企業別収益 (2020-2025)
  • 欧州の市場規模：タイプ別
  • 欧州の市場規模：用途別
  • 欧州の市場 トレンドと機会
• 中国の市場: Pレイヤー, セグメントs and 下流
  • 中国のマルチがん早期スクリーニング 企業別収益 (2020-2025)
  • 中国の市場規模：タイプ別
  • 中国の市場規模：用途別
  • 中国の市場 トレンドと機会
• 日本の市場: Pレイヤー, セグメントs and 下流
  • 日本のマルチがん早期スクリーニング 企業別収益 (2020-2025)
  • 日本の市場規模：タイプ別
  • 日本の市場規模：用途別
  • 日本の市場 トレンドと機会
• 東南アジア 市場: Pレイヤー, セグメントs and 下流
  • 東南アジア マルチがん早期スクリーニング 企業別収益 (2020-2025)
  • 東南アジア 市場規模：タイプ別
  • 東南アジア 市場規模：用途別
  • 東南アジア 市場 トレンドと機会
• インド 市場: Pレイヤー, セグメントs and 下流
  • インド マルチがん早期スクリーニング 企業別収益 (2020-2025)
  • インド 市場規模：タイプ別
  • インド 市場規模：用途別
  • インド 市場 トレンドと機会

第7章 主要企業のプロファイル

• Guardant Health
• Exact Sciences
• Freenome
• Epiginomics AG
• Bio-techne
• ThriveEarlier Detection
• GRAIL, Inc.
• CellMax life
• Berry Genomics
• Singlera Genomics
• Geneseeq
• BGI Genomics
• Burning Rock Biotech Limited
• New Horizon Health Limited
• Yeasen Bio
• Hangzhou Aoru Biotech
• Amoy Diagnostics Co., Ltd.
• Genetron Health
• AnchorDx
• Surexam Bio-Tech Co.,Ltd.
• HaploX
• HefeiLaierBiotechnologyCo.,Ltd

第8章 マルチがん早期スクリーニング 市場動向

• マルチがん早期スクリーニング 業界動向
• マルチがん早期スクリーニング 市場の促進要因
• マルチがん早期スクリーニング 市場の課題
• マルチがん早期スクリーニング 市場の抑制要因

第9章 市場調査結果と結論

第10章 付録

List of Tables

Table 1. Global Multi-Cancer Early Screening Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global Multi-Cancer Early Screening Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Market Multi-Cancer Early Screening Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Multi-Cancer Early Screening Revenue (US$ Million) Market Share by Region (2020-2025)

Table 5. Global Multi-Cancer Early Screening Revenue Share by Region (2020-2025)

Table 6. Global Multi-Cancer Early Screening Revenue (US$ Million) Forecast by Region (2026-2031)

Table 7. Global Multi-Cancer Early Screening Revenue Share Forecast by Region (2026-2031)

Table 8. Global Multi-Cancer Early Screening Market Size by Type (2020-2025) & (US$ Million)

Table 9. Global Multi-Cancer Early Screening Revenue Market Share by Type (2020-2025)

Table 10. Global Multi-Cancer Early Screening Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 11. Global Multi-Cancer Early Screening Revenue Market Share by Type (2026-2031)

Table 12. Representative Players of Each Type

Table 13. Global Multi-Cancer Early Screening Market Size by Application (2020-2025) & (US$ Million)

Table 14. Global Multi-Cancer Early Screening Revenue Market Share by Application (2020-2025)

Table 15. Global Multi-Cancer Early Screening Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 16. Global Multi-Cancer Early Screening Revenue Market Share by Application (2026-2031)

Table 17. New Sources of Growth in Multi-Cancer Early Screening Application

Table 18. Global Multi-Cancer Early Screening Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Multi-Cancer Early Screening Market Share by Players (2020-2025)

Table 20. Global Top Multi-Cancer Early Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multi-Cancer Early Screening as of 2024)

Table 21. Ranking of Global Top Multi-Cancer Early Screening Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Multi-Cancer Early Screening Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Multi-Cancer Early Screening, Headquarters and Area Served

Table 24. Global Key Players of Multi-Cancer Early Screening, Product and Application

Table 25. Global Key Players of Multi-Cancer Early Screening, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America Multi-Cancer Early Screening Revenue by Company (2020-2025) & (US$ Million)

Table 28. North America Multi-Cancer Early Screening Revenue Market Share by Company (2020-2025)

Table 29. North America Multi-Cancer Early Screening Market Size by Type (2020-2025) & (US$ Million)

Table 30. North America Multi-Cancer Early Screening Market Size by Application (2020-2025) & (US$ Million)

Table 31. Europe Multi-Cancer Early Screening Revenue by Company (2020-2025) & (US$ Million)

Table 32. Europe Multi-Cancer Early Screening Revenue Market Share by Company (2020-2025)

Table 33. Europe Multi-Cancer Early Screening Market Size by Type (2020-2025) & (US$ Million)

Table 34. Europe Multi-Cancer Early Screening Market Size by Application (2020-2025) & (US$ Million)

Table 35. China Multi-Cancer Early Screening Revenue by Company (2020-2025) & (US$ Million)

Table 36. China Multi-Cancer Early Screening Revenue Market Share by Company (2020-2025)

Table 37. China Multi-Cancer Early Screening Market Size by Type (2020-2025) & (US$ Million)

Table 38. China Multi-Cancer Early Screening Market Size by Application (2020-2025) & (US$ Million)

Table 39. Japan Multi-Cancer Early Screening Revenue by Company (2020-2025) & (US$ Million)

Table 40. Japan Multi-Cancer Early Screening Revenue Market Share by Company (2020-2025)

Table 41. Japan Multi-Cancer Early Screening Market Size by Type (2020-2025) & (US$ Million)

Table 42. Japan Multi-Cancer Early Screening Market Size by Application (2020-2025) & (US$ Million)

Table 43. Southeast Asia Multi-Cancer Early Screening Revenue by Company (2020-2025) & (US$ Million)

Table 44. Southeast Asia Multi-Cancer Early Screening Revenue Market Share by Company (2020-2025)

Table 45. Southeast Asia Multi-Cancer Early Screening Market Size by Type (2020-2025) & (US$ Million)

Table 46. Southeast Asia Multi-Cancer Early Screening Market Size by Application (2020-2025) & (US$ Million)

Table 47. India Multi-Cancer Early Screening Revenue by Company (2020-2025) & (US$ Million)

Table 48. India Multi-Cancer Early Screening Revenue Market Share by Company (2020-2025)

Table 49. India Multi-Cancer Early Screening Market Size by Type (2020-2025) & (US$ Million)

Table 50. India Multi-Cancer Early Screening Market Size by Application (2020-2025) & (US$ Million)

Table 51. Guardant Health Company Details

Table 52. Guardant Health Business Overview

Table 53. Guardant Health Multi-Cancer Early Screening Product

Table 54. Guardant Health Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 55. Guardant Health Recent Development

Table 56. Exact Sciences Company Details

Table 57. Exact Sciences Business Overview

Table 58. Exact Sciences Multi-Cancer Early Screening Product

Table 59. Exact Sciences Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 60. Exact Sciences Recent Development

Table 61. Freenome Company Details

Table 62. Freenome Business Overview

Table 63. Freenome Multi-Cancer Early Screening Product

Table 64. Freenome Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 65. Freenome Recent Development

Table 66. Epiginomics AG Company Details

Table 67. Epiginomics AG Business Overview

Table 68. Epiginomics AG Multi-Cancer Early Screening Product

Table 69. Epiginomics AG Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 70. Epiginomics AG Recent Development

Table 71. Bio-techne Company Details

Table 72. Bio-techne Business Overview

Table 73. Bio-techne Multi-Cancer Early Screening Product

Table 74. Bio-techne Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 75. Bio-techne Recent Development

Table 76. ThriveEarlier Detection Company Details

Table 77. ThriveEarlier Detection Business Overview

Table 78. ThriveEarlier Detection Multi-Cancer Early Screening Product

Table 79. ThriveEarlier Detection Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 80. ThriveEarlier Detection Recent Development

Table 81. GRAIL, Inc. Company Details

Table 82. GRAIL, Inc. Business Overview

Table 83. GRAIL, Inc. Multi-Cancer Early Screening Product

Table 84. GRAIL, Inc. Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 85. GRAIL, Inc. Recent Development

Table 86. CellMax life Company Details

Table 87. CellMax life Business Overview

Table 88. CellMax life Multi-Cancer Early Screening Product

Table 89. CellMax life Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 90. CellMax life Recent Development

Table 91. Berry Genomics Company Details

Table 92. Berry Genomics Business Overview

Table 93. Berry Genomics Multi-Cancer Early Screening Product

Table 94. Berry Genomics Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 95. Berry Genomics Recent Development

Table 96. Singlera Genomics Company Details

Table 97. Singlera Genomics Business Overview

Table 98. Singlera Genomics Multi-Cancer Early Screening Product

Table 99. Singlera Genomics Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 100. Singlera Genomics Recent Development

Table 101. Geneseeq Company Details

Table 102. Geneseeq Business Overview

Table 103. Geneseeq Multi-Cancer Early Screening Product

Table 104. Geneseeq Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 105. Geneseeq Recent Development

Table 106. BGI Genomics Company Details

Table 107. BGI Genomics Business Overview

Table 108. BGI Genomics Multi-Cancer Early Screening Product

Table 109. BGI Genomics Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 110. BGI Genomics Recent Development

Table 111. Burning Rock Biotech Limited Company Details

Table 112. Burning Rock Biotech Limited Business Overview

Table 113. Burning Rock Biotech Limited Multi-Cancer Early Screening Product

Table 114. Burning Rock Biotech Limited Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 115. Burning Rock Biotech Limited Recent Development

Table 116. New Horizon Health Limited Company Details

Table 117. New Horizon Health Limited Business Overview

Table 118. New Horizon Health Limited Multi-Cancer Early Screening Product

Table 119. New Horizon Health Limited Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 120. New Horizon Health Limited Recent Development

Table 121. Yeasen Bio Company Details

Table 122. Yeasen Bio Business Overview

Table 123. Yeasen Bio Multi-Cancer Early Screening Product

Table 124. Yeasen Bio Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 125. Yeasen Bio Recent Development

Table 126. Hangzhou Aoru Biotech Company Details

Table 127. Hangzhou Aoru Biotech Business Overview

Table 128. Hangzhou Aoru Biotech Multi-Cancer Early Screening Product

Table 129. Hangzhou Aoru Biotech Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 130. Hangzhou Aoru Biotech Recent Development

Table 131. Amoy Diagnostics Co., Ltd. Company Details

Table 132. Amoy Diagnostics Co., Ltd. Business Overview

Table 133. Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Product

Table 134. Amoy Diagnostics Co., Ltd. Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 135. Amoy Diagnostics Co., Ltd. Recent Development

Table 136. Genetron Health Company Details

Table 137. Genetron Health Business Overview

Table 138. Genetron Health Multi-Cancer Early Screening Product

Table 139. Genetron Health Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 140. Genetron Health Recent Development

Table 141. AnchorDx Company Details

Table 142. AnchorDx Business Overview

Table 143. AnchorDx Multi-Cancer Early Screening Product

Table 144. AnchorDx Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 145. AnchorDx Recent Development

Table 146. Surexam Bio-Tech Co.,Ltd. Company Details

Table 147. Surexam Bio-Tech Co.,Ltd. Business Overview

Table 148. Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Product

Table 149. Surexam Bio-Tech Co.,Ltd. Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 150. Surexam Bio-Tech Co.,Ltd. Recent Development

Table 151. HaploX Company Details

Table 152. HaploX Business Overview

Table 153. HaploX Multi-Cancer Early Screening Product

Table 154. HaploX Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 155. HaploX Recent Development

Table 156. HefeiLaierBiotechnologyCo.,Ltd Company Details

Table 157. HefeiLaierBiotechnologyCo.,Ltd Business Overview

Table 158. HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Product

Table 159. HefeiLaierBiotechnologyCo.,Ltd Revenue in Multi-Cancer Early Screening Business (2020-2025) & (US$ Million)

Table 160. HefeiLaierBiotechnologyCo.,Ltd Recent Development

Table 161. Multi-Cancer Early Screening Market Trends

Table 162. Multi-Cancer Early Screening Market Drivers

Table 163. Multi-Cancer Early Screening Market Challenges

Table 164. Multi-Cancer Early Screening Market Restraints

Table 165. Research Programs/Design for This Report

Table 166. Key Data Information from Secondary Sources

Table 167. Key Data Information from Primary Sources

List of Figures

Figure 1. Multi-Cancer Early Screening Product Picture

Figure 2. Global Multi-Cancer Early Screening Market Share by Type: 2024 VS 2031

Figure 3. cfDNA Methylation Features

Figure 4. Low-pass WGS Features

Figure 5. Protein Marker Combination Features

Figure 6. Multi-omics Integrated Analysis Features

Figure 7. Global Multi-Cancer Early Screening Market Share by Application: 2024 VS 2031

Figure 8. Medical Institutions

Figure 9. Physical Examination Centers

Figure 10. Multi-Cancer Early Screening Report Years Considered

Figure 11. Global Multi-Cancer Early Screening Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global Multi-Cancer Early Screening Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Multi-Cancer Early Screening Revenue Market Share by Region: 2020 VS 2024

Figure 14. North America Multi-Cancer Early Screening Revenue (US$ Million) Growth Rate (2020-2031)

Figure 15. Europe Multi-Cancer Early Screening Revenue (US$ Million) Growth Rate (2020-2031)

Figure 16. China Multi-Cancer Early Screening Revenue (US$ Million) Growth Rate (2020-2031)

Figure 17. Japan Multi-Cancer Early Screening Revenue (US$ Million) Growth Rate (2020-2031)

Figure 18. Southeast Asia Multi-Cancer Early Screening Revenue (US$ Million) Growth Rate (2020-2031)

Figure 19. India Multi-Cancer Early Screening Revenue (US$ Million) Growth Rate (2020-2031)

Figure 20. South America Multi-Cancer Early Screening Revenue (US$ Million) Growth Rate (2020-2031)

Figure 21. Middle East Multi-Cancer Early Screening Revenue (US$ Million) Growth Rate (2020-2031)

Figure 22. Global Multi-Cancer Early Screening Market Share by Players in 2024

Figure 23. Global Top Multi-Cancer Early Screening Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multi-Cancer Early Screening as of 2024)

Figure 24. The Top 10 and 5 Players Market Share by Multi-Cancer Early Screening Revenue in 2024

Figure 25. North America Multi-Cancer Early Screening Market Share by Type (2020-2025)

Figure 26. North America Multi-Cancer Early Screening Market Share by Application (2020-2025)

Figure 27. Europe Multi-Cancer Early Screening Market Share by Type (2020-2025)

Figure 28. Europe Multi-Cancer Early Screening Market Share by Application (2020-2025)

Figure 29. China Multi-Cancer Early Screening Market Share by Type (2020-2025)

Figure 30. China Multi-Cancer Early Screening Market Share by Application (2020-2025)

Figure 31. Japan Multi-Cancer Early Screening Market Share by Type (2020-2025)

Figure 32. Japan Multi-Cancer Early Screening Market Share by Application (2020-2025)

Figure 33. Southeast Asia Multi-Cancer Early Screening Market Share by Type (2020-2025)

Figure 34. Southeast Asia Multi-Cancer Early Screening Market Share by Application (2020-2025)

Figure 35. India Multi-Cancer Early Screening Market Share by Type (2020-2025)

Figure 36. India Multi-Cancer Early Screening Market Share by Application (2020-2025)

Figure 37. Guardant Health Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 38. Exact Sciences Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 39. Freenome Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 40. Epiginomics AG Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 41. Bio-techne Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 42. ThriveEarlier Detection Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 43. GRAIL, Inc. Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 44. CellMax life Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 45. Berry Genomics Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 46. Singlera Genomics Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 47. Geneseeq Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 48. BGI Genomics Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 49. Burning Rock Biotech Limited Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 50. New Horizon Health Limited Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 51. Yeasen Bio Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 52. Hangzhou Aoru Biotech Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 53. Amoy Diagnostics Co., Ltd. Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 54. Genetron Health Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 55. AnchorDx Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 56. Surexam Bio-Tech Co.,Ltd. Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 57. HaploX Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 58. HefeiLaierBiotechnologyCo.,Ltd Revenue Growth Rate in Multi-Cancer Early Screening Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

This research report focuses on the Multi-Cancer Early Screening Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Report Overview

• 1.1 Study Scope
• 1.2 Market by Type
  • 1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
  • 1.2.2 cfDNA Methylation
  • 1.2.3 Low-pass WGS
  • 1.2.4 Protein Marker Combination
  • 1.2.5 Multi-omics Integrated Analysis
• 1.3 Market by Application
  • 1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
  • 1.3.2 Medical Institutions
  • 1.3.3 Physical Examination Centers
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Multi-Cancer Early Screening Market Perspective (2020-2031)
• 2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
• 2.3 Global Multi-Cancer Early Screening Revenue Market Share by Region (2020-2025)
• 2.4 Global Multi-Cancer Early Screening Revenue Forecast by Region (2026-2031)
• 2.5 Major Region and Emerging Market Analysis
  • 2.5.1 North America Multi-Cancer Early Screening Market Size and Prospective (2020-2031)
  • 2.5.2 Europe Multi-Cancer Early Screening Market Size and Prospective (2020-2031)
  • 2.5.3 China Multi-Cancer Early Screening Market Size and Prospective (2020-2031)
  • 2.5.4 Japan Multi-Cancer Early Screening Market Size and Prospective (2020-2031)
  • 2.5.5 Southeast Asia Multi-Cancer Early Screening Market Size and Prospective (2020-2031)
  • 2.5.6 India Multi-Cancer Early Screening Market Size and Prospective (2020-2031)
  • 2.5.7 South America Multi-Cancer Early Screening Market Size and Prospective (2020-2031)
  • 2.5.8 Middle East Multi-Cancer Early Screening Market Size and Prospective (2020-2031)

3 Breakdown Data by Type

• 3.1 Global Multi-Cancer Early Screening Historic Market Size by Type (2020-2025)
• 3.2 Global Multi-Cancer Early Screening Forecasted Market Size by Type (2026-2031)
• 3.3 Different Types Multi-Cancer Early Screening Representative Players

4 Breakdown Data by Application

• 4.1 Global Multi-Cancer Early Screening Historic Market Size by Application (2020-2025)
• 4.2 Global Multi-Cancer Early Screening Forecasted Market Size by Application (2026-2031)
• 4.3 New Sources of Growth in Multi-Cancer Early Screening Application

5 Competition Landscape by Players

• 5.1 Global Top Players by Revenue
  • 5.1.1 Global Top Multi-Cancer Early Screening Players by Revenue (2020-2025)
  • 5.1.2 Global Multi-Cancer Early Screening Revenue Market Share by Players (2020-2025)
• 5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 5.3 Players Covered: Ranking by Multi-Cancer Early Screening Revenue
• 5.4 Global Multi-Cancer Early Screening Market Concentration Analysis
  • 5.4.1 Global Multi-Cancer Early Screening Market Concentration Ratio (CR5 and HHI)
  • 5.4.2 Global Top 10 and Top 5 Companies by Multi-Cancer Early Screening Revenue in 2024
• 5.5 Global Key Players of Multi-Cancer Early Screening Head office and Area Served
• 5.6 Global Key Players of Multi-Cancer Early Screening, Product and Application
• 5.7 Global Key Players of Multi-Cancer Early Screening, Date of Enter into This Industry
• 5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

• 6.1 North America Market: Players, Segments and Downstream
  • 6.1.1 North America Multi-Cancer Early Screening Revenue by Company (2020-2025)
  • 6.1.2 North America Market Size by Type
    • 6.1.2.1 North America Multi-Cancer Early Screening Market Size by Type (2020-2025)
    • 6.1.2.2 North America Multi-Cancer Early Screening Market Share by Type (2020-2025)
  • 6.1.3 North America Market Size by Application
    • 6.1.3.1 North America Multi-Cancer Early Screening Market Size by Application (2020-2025)
    • 6.1.3.2 North America Multi-Cancer Early Screening Market Share by Application (2020-2025)
  • 6.1.4 North America Market Trend and Opportunities
• 6.2 Europe Market: Players, Segments and Downstream
  • 6.2.1 Europe Multi-Cancer Early Screening Revenue by Company (2020-2025)
  • 6.2.2 Europe Market Size by Type
    • 6.2.2.1 Europe Multi-Cancer Early Screening Market Size by Type (2020-2025)
    • 6.2.2.2 Europe Multi-Cancer Early Screening Market Share by Type (2020-2025)
  • 6.2.3 Europe Market Size by Application
    • 6.2.3.1 Europe Multi-Cancer Early Screening Market Size by Application (2020-2025)
    • 6.2.3.2 Europe Multi-Cancer Early Screening Market Share by Application (2020-2025)
  • 6.2.4 Europe Market Trend and Opportunities
• 6.3 China Market: Players, Segments and Downstream
  • 6.3.1 China Multi-Cancer Early Screening Revenue by Company (2020-2025)
  • 6.3.2 China Market Size by Type
    • 6.3.2.1 China Multi-Cancer Early Screening Market Size by Type (2020-2025)
    • 6.3.2.2 China Multi-Cancer Early Screening Market Share by Type (2020-2025)
  • 6.3.3 China Market Size by Application
    • 6.3.3.1 China Multi-Cancer Early Screening Market Size by Application (2020-2025)
    • 6.3.3.2 China Multi-Cancer Early Screening Market Share by Application (2020-2025)
  • 6.3.4 China Market Trend and Opportunities
• 6.4 Japan Market: Players, Segments and Downstream
  • 6.4.1 Japan Multi-Cancer Early Screening Revenue by Company (2020-2025)
  • 6.4.2 Japan Market Size by Type
    • 6.4.2.1 Japan Multi-Cancer Early Screening Market Size by Type (2020-2025)
    • 6.4.2.2 Japan Multi-Cancer Early Screening Market Share by Type (2020-2025)
  • 6.4.3 Japan Market Size by Application
    • 6.4.3.1 Japan Multi-Cancer Early Screening Market Size by Application (2020-2025)
    • 6.4.3.2 Japan Multi-Cancer Early Screening Market Share by Application (2020-2025)
  • 6.4.4 Japan Market Trend and Opportunities
• 6.5 Southeast Asia Market: Players, Segments and Downstream
  • 6.5.1 Southeast Asia Multi-Cancer Early Screening Revenue by Company (2020-2025)
  • 6.5.2 Southeast Asia Market Size by Type
    • 6.5.2.1 Southeast Asia Multi-Cancer Early Screening Market Size by Type (2020-2025)
    • 6.5.2.2 Southeast Asia Multi-Cancer Early Screening Market Share by Type (2020-2025)
  • 6.5.3 Southeast Asia Market Size by Application
    • 6.5.3.1 Southeast Asia Multi-Cancer Early Screening Market Size by Application (2020-2025)
    • 6.5.3.2 Southeast Asia Multi-Cancer Early Screening Market Share by Application (2020-2025)
  • 6.5.4 Southeast Asia Market Trend and Opportunities
• 6.6 India Market: Players, Segments and Downstream
  • 6.6.1 India Multi-Cancer Early Screening Revenue by Company (2020-2025)
  • 6.6.2 India Market Size by Type
    • 6.6.2.1 India Multi-Cancer Early Screening Market Size by Type (2020-2025)
    • 6.6.2.2 India Multi-Cancer Early Screening Market Share by Type (2020-2025)
  • 6.6.3 India Market Size by Application
    • 6.6.3.1 India Multi-Cancer Early Screening Market Size by Application (2020-2025)
    • 6.6.3.2 India Multi-Cancer Early Screening Market Share by Application (2020-2025)
  • 6.6.4 India Market Trend and Opportunities

7 Key Players Profiles

• 7.1 Guardant Health
  • 7.1.1 Guardant Health Company Details
  • 7.1.2 Guardant Health Business Overview
  • 7.1.3 Guardant Health Multi-Cancer Early Screening Introduction
  • 7.1.4 Guardant Health Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.1.5 Guardant Health Recent Development
• 7.2 Exact Sciences
  • 7.2.1 Exact Sciences Company Details
  • 7.2.2 Exact Sciences Business Overview
  • 7.2.3 Exact Sciences Multi-Cancer Early Screening Introduction
  • 7.2.4 Exact Sciences Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.2.5 Exact Sciences Recent Development
• 7.3 Freenome
  • 7.3.1 Freenome Company Details
  • 7.3.2 Freenome Business Overview
  • 7.3.3 Freenome Multi-Cancer Early Screening Introduction
  • 7.3.4 Freenome Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.3.5 Freenome Recent Development
• 7.4 Epiginomics AG
  • 7.4.1 Epiginomics AG Company Details
  • 7.4.2 Epiginomics AG Business Overview
  • 7.4.3 Epiginomics AG Multi-Cancer Early Screening Introduction
  • 7.4.4 Epiginomics AG Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.4.5 Epiginomics AG Recent Development
• 7.5 Bio-techne
  • 7.5.1 Bio-techne Company Details
  • 7.5.2 Bio-techne Business Overview
  • 7.5.3 Bio-techne Multi-Cancer Early Screening Introduction
  • 7.5.4 Bio-techne Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.5.5 Bio-techne Recent Development
• 7.6 ThriveEarlier Detection
  • 7.6.1 ThriveEarlier Detection Company Details
  • 7.6.2 ThriveEarlier Detection Business Overview
  • 7.6.3 ThriveEarlier Detection Multi-Cancer Early Screening Introduction
  • 7.6.4 ThriveEarlier Detection Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.6.5 ThriveEarlier Detection Recent Development
• 7.7 GRAIL, Inc.
  • 7.7.1 GRAIL, Inc. Company Details
  • 7.7.2 GRAIL, Inc. Business Overview
  • 7.7.3 GRAIL, Inc. Multi-Cancer Early Screening Introduction
  • 7.7.4 GRAIL, Inc. Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.7.5 GRAIL, Inc. Recent Development
• 7.8 CellMax life
  • 7.8.1 CellMax life Company Details
  • 7.8.2 CellMax life Business Overview
  • 7.8.3 CellMax life Multi-Cancer Early Screening Introduction
  • 7.8.4 CellMax life Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.8.5 CellMax life Recent Development
• 7.9 Berry Genomics
  • 7.9.1 Berry Genomics Company Details
  • 7.9.2 Berry Genomics Business Overview
  • 7.9.3 Berry Genomics Multi-Cancer Early Screening Introduction
  • 7.9.4 Berry Genomics Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.9.5 Berry Genomics Recent Development
• 7.10 Singlera Genomics
  • 7.10.1 Singlera Genomics Company Details
  • 7.10.2 Singlera Genomics Business Overview
  • 7.10.3 Singlera Genomics Multi-Cancer Early Screening Introduction
  • 7.10.4 Singlera Genomics Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.10.5 Singlera Genomics Recent Development
• 7.11 Geneseeq
  • 7.11.1 Geneseeq Company Details
  • 7.11.2 Geneseeq Business Overview
  • 7.11.3 Geneseeq Multi-Cancer Early Screening Introduction
  • 7.11.4 Geneseeq Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.11.5 Geneseeq Recent Development
• 7.12 BGI Genomics
  • 7.12.1 BGI Genomics Company Details
  • 7.12.2 BGI Genomics Business Overview
  • 7.12.3 BGI Genomics Multi-Cancer Early Screening Introduction
  • 7.12.4 BGI Genomics Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.12.5 BGI Genomics Recent Development
• 7.13 Burning Rock Biotech Limited
  • 7.13.1 Burning Rock Biotech Limited Company Details
  • 7.13.2 Burning Rock Biotech Limited Business Overview
  • 7.13.3 Burning Rock Biotech Limited Multi-Cancer Early Screening Introduction
  • 7.13.4 Burning Rock Biotech Limited Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.13.5 Burning Rock Biotech Limited Recent Development
• 7.14 New Horizon Health Limited
  • 7.14.1 New Horizon Health Limited Company Details
  • 7.14.2 New Horizon Health Limited Business Overview
  • 7.14.3 New Horizon Health Limited Multi-Cancer Early Screening Introduction
  • 7.14.4 New Horizon Health Limited Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.14.5 New Horizon Health Limited Recent Development
• 7.15 Yeasen Bio
  • 7.15.1 Yeasen Bio Company Details
  • 7.15.2 Yeasen Bio Business Overview
  • 7.15.3 Yeasen Bio Multi-Cancer Early Screening Introduction
  • 7.15.4 Yeasen Bio Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.15.5 Yeasen Bio Recent Development
• 7.16 Hangzhou Aoru Biotech
  • 7.16.1 Hangzhou Aoru Biotech Company Details
  • 7.16.2 Hangzhou Aoru Biotech Business Overview
  • 7.16.3 Hangzhou Aoru Biotech Multi-Cancer Early Screening Introduction
  • 7.16.4 Hangzhou Aoru Biotech Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.16.5 Hangzhou Aoru Biotech Recent Development
• 7.17 Amoy Diagnostics Co., Ltd.
  • 7.17.1 Amoy Diagnostics Co., Ltd. Company Details
  • 7.17.2 Amoy Diagnostics Co., Ltd. Business Overview
  • 7.17.3 Amoy Diagnostics Co., Ltd. Multi-Cancer Early Screening Introduction
  • 7.17.4 Amoy Diagnostics Co., Ltd. Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.17.5 Amoy Diagnostics Co., Ltd. Recent Development
• 7.18 Genetron Health
  • 7.18.1 Genetron Health Company Details
  • 7.18.2 Genetron Health Business Overview
  • 7.18.3 Genetron Health Multi-Cancer Early Screening Introduction
  • 7.18.4 Genetron Health Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.18.5 Genetron Health Recent Development
• 7.19 AnchorDx
  • 7.19.1 AnchorDx Company Details
  • 7.19.2 AnchorDx Business Overview
  • 7.19.3 AnchorDx Multi-Cancer Early Screening Introduction
  • 7.19.4 AnchorDx Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.19.5 AnchorDx Recent Development
• 7.20 Surexam Bio-Tech Co.,Ltd.
  • 7.20.1 Surexam Bio-Tech Co.,Ltd. Company Details
  • 7.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
  • 7.20.3 Surexam Bio-Tech Co.,Ltd. Multi-Cancer Early Screening Introduction
  • 7.20.4 Surexam Bio-Tech Co.,Ltd. Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.20.5 Surexam Bio-Tech Co.,Ltd. Recent Development
• 7.21 HaploX
  • 7.21.1 HaploX Company Details
  • 7.21.2 HaploX Business Overview
  • 7.21.3 HaploX Multi-Cancer Early Screening Introduction
  • 7.21.4 HaploX Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.21.5 HaploX Recent Development
• 7.22 HefeiLaierBiotechnologyCo.,Ltd
  • 7.22.1 HefeiLaierBiotechnologyCo.,Ltd Company Details
  • 7.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
  • 7.22.3 HefeiLaierBiotechnologyCo.,Ltd Multi-Cancer Early Screening Introduction
  • 7.22.4 HefeiLaierBiotechnologyCo.,Ltd Revenue in Multi-Cancer Early Screening Business (2020-2025)
  • 7.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Development

8 Multi-Cancer Early Screening Market Dynamics

• 8.1 Multi-Cancer Early Screening Industry Trends
• 8.2 Multi-Cancer Early Screening Market Drivers
• 8.3 Multi-Cancer Early Screening Market Challenges
• 8.4 Multi-Cancer Early Screening Market Restraints

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer